Pembrolizumab and BCG after scope removal of upper urinary tract cancer
Part of Cancer, Kidney & urinary clinical trials.
This trial tests combining the immunotherapy drug pembrolizumab with BCG, a standard treatment for bladder cancer, after a scope procedure to remove high-grade cancer from the upper urinary tract. It aims to lower the chance of cancer coming back without needing to remove the kidney.
Summary written for real people, not researchers, by Clin2.
Who can take part
- 18 years or older
- High-grade cancer in the lining of the kidney or ureter (upper urinary tract)
- All visible cancer can be completely removed during a scope procedure
- Unwilling or not healthy enough for surgery to remove the whole kidney
- No cancer spread to other parts of the body
- No prior immunotherapy (like pembrolizumab or ipilimumab)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether bicalutamide can improve outcomes for people with non-muscle-invasive bladder cancer who are starting BCG through the bladder. It may help prevent cancer from coming back or progressing after BCG.
This trial tests a combination of chemotherapy placed directly into the bladder and an immunotherapy drug called pembrolizumab (given through a vein) for people with high-risk bladder cancer that has not completely responded to or has returned after BCG treatment.
This trial tests a combination of two treatments after bladder tumor surgery: a drug called toripalimab (given through a vein) plus BCG therapy (given into the bladder) for people with high-risk non-muscle-invasive bladder cancer. The goal is to see if this combination can help prevent the cancer from coming back.
This trial tests whether a specific schedule of BCG (a weakened germ that boosts the immune system) placed directly into the bladder is safe and effective for medium- to high-risk bladder cancer that hasn't grown into the muscle. It aims to see if adjusting the standard BCG course can work better for people with a PD-L1-positive tumor.
This trial studies a BCG-based bladder instillation in people with newly diagnosed, intermediate- or high-risk non-muscle invasive bladder cancer who have had their tumor fully removed. The goal is to see whether this treatment is safer and works better to lower the chance of the cancer coming back.
This study tests a newer way to remove bladder tumors (called ERBT) combined with BCG, a standard immunotherapy placed in the bladder, for people with bladder cancer that is not too advanced. The goal is to see if this combination helps reduce the chance of the cancer coming back.
Hear when a new High Risk Superficial Upper Urinary Tract Transitional Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.